Occurrence of HLA- and non-HLA antibodies after heart transplantation are associated with cardiac allograft vasculopathy

Up to the present, ECGs have been classified on the basis of the analysis of the ECG curve shape. But…

To overcome numerous contradictions in the knowledge of the blood transportation, a hypothesis was supposed asserting the swirling pattern of…

The paper reveals logical relationships between events, facts and results of research studies and exemplary materials of practical applications of…

Arrhythmogenic right ventricular dysplasia is a rare entity and a significant cause of sudden death especially in the Italian population…

Original research

Occurrence of HLA- and non-HLA antibodies after heart transplantation are associated with cardiac allograft vasculopathy

Maja-Theresa Dieterlen1Jens Garbade1Robert Riede1Stefan Dhein1Friedrich W. Mohr1Hartmuth B. Bittner2Markus J. Barten1*

1 University of Leipzig, Department of Cardiac Surgery, Heart Center, 04289 Leipzig, Germany
2 Florida Hospital Orlando, Department Cardiothoracic Transplantation and Advanced Cardiac Surgery, Orlando, Florida, USA

* Corresponding author:
   +49 (341) 865-14-21
  This email address is being protected from spambots. You need JavaScript enabled to view it.


Cardiac allograft vasculopathy (CAV) accounts for major morbidity and mortality late in the heart transplant (HTx) history. The role of antibodies (Abs) directed against human leukocyte antigens (HLA) and non-HLA antigens in the pathogenesis of CAV are still under investigation.

Materials and methods

Sera of 116 long-term HTx recipients with CAV (n=46) and without CAV (n=70) were analysed by (1) Luminex for Abs against both HLA classes and major histocompatibility complex class I-related chain A (MICA), and by (2) ELISA for Abs against angiotensin-type-1-receptor (AT1R) or endothelin-receptor-A (ETAR). Cellular rejection by endomyocardial biopsies and immunosuppressive drug therapy were analysed, too.


HTx recipients developed higher levels of non-HLA-Abs than of Abs against HLA. CAV appeared more frequently in recipients with non-HLA-Abs (38.3% AT1R; 44.1% ETAR; 13.0% MICA) than in recipients with HLA-Abs (8.7% HLA class I; 8.7% HLA class II). Recipients with non-HLA-Abs developed CAV earlier (73.7±47.4months) than recipients without Abs (85.5±50.6months).


Occurrence of HLA-Abs and non-HLA-Abs contribute to CAV after HTx. Non-HLA-Abs were connected to an earlier and higher incidence of CAV. Recipients with subclinical cellular rejections and AT1R-Abs and ETAR-Abs as well as recipients with certain donor specific-Abs again HLA and MICA specifities are at risk to develop CAV.


Maja-Theresa Dieterlen, Jens Garbade, Robert Riede, Stefan Dhein, Friedrich W. Mohr, Hartmuth B. Bittner, Markus J. Barten. Occurrence of HLA- and non-HLA antibodies after heart transplantation are associated with cardiac allograft vasculopathy; Cardiometry; No.4; May 2014; p.71-85; DOI:10.12710/cardiometry.2014.4.7185 Available from: http://www.cardiometry.net/no4-may-2014/cardiac-allograft-vasculopathy



Our book in WoS™ Core Collection

We are glad to inform you that the book "Theoretical principles of heart cycle phase analysis" written by researchers from Russian New University has been accepted and indexed in The Book Citation Index in Web of Science™ Core Collection


Founders of a new fundamental science: Cardiometry





Russian New University

Your online partner for English language editing, proofreading, medical writing, formatting, design & development and publication support services

Online ECG / Telemetry Certification Course

Teach you everything you need to interpret arrhythmia and administer a 12-lead EKG

Cardiocode - unique diagnostics of the heart